Trial Profile
Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH)
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Nomacopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Acronyms CAPSTONE
- Sponsors Akari Therapeutics
- 11 Dec 2020 According to a Akari Therapeutics media release, full clinical details on all 19 PNH patients treated with nomacopan will be provided in a manuscript that is currently in preparation.
- 11 Dec 2020 Results (n=19) derived from COBALT, CAPSTONE and long-term safety study CONSERVE presented in an Akari Therapeutics Media Release.
- 21 Jan 2020 This trial is completed in Lithuania as per European Clinical Trials Database record